This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $536,836.00 to The University of Texas M.D. Anderson Cancer Center to conduct research on the delivery optimization of a transarterial ablative therapy for treating hepatocellular carcinoma (HCC). The research aims to develop mathematical models that accurately describe the thermal, hypoxic, and pH response of this therapeutic approach in biological tissues, and to...
This federal Project Grant award for $599,191, provided by the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research program), supports the development and validation of a 3D dynamic contrast-enhanced ultrasound (3D DCE-US) framework to characterize tumor vascular properties for liver malignancies. The goal is to introduce computational approaches that leverage the interconnected nature of voxels in 3D DCE-US imaging to capture new information beyond conventional...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will provide $159,636 to the University of Wisconsin-Madison over 5 years starting August 1, 2024. The purpose of the award is to support the development of a translational research program led by Dr. Quaovi Sodji that investigates using low-dose targeted radionuclide therapy (TRT) to enhance the efficacy of chimeric antigen receptor (CAR) T cell therapy against neuroblastoma, a deadly...
This Project Grant award of $677,998 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) will support research by The Medical College of Wisconsin, Inc. (MCW) to externally validate and integrate radio-pathomic models for delineating the true extent of glioma tumor infiltration. The research aims to develop non-invasive tools to aid in glioma treatment planning, monitoring treatment response, and guiding personalized therapies. Specifically, the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $131,910 to Virginia Polytechnic Institute & State University (Virginia Tech) to investigate treatment strategies and clinical outcomes of histotripsy, a non-thermal ablation technique, for complete ablation of osteosarcoma in canine models. The key objectives are to: 1) investigate the treatment parameters and strategies needed for complete ablation of ex vivo canine...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the federal Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), is funding the development of a Transcranial Magnetic Resonance (MR) and Ultrasound (US) Guided Histotripsy (TCMR-USGHT) system for the non-invasive treatment of brain tumors. The $543,959 award to the Regents of the University of Michigan aims to advance this novel...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $357,939 to the University of California, Davis to develop a personalized "liver digital twin" simulation platform. The goal is to optimize liver transarterial embolization (TAE) treatment for liver cancer patients, including TAE, transarterial radioembolization (TARE), and transarterial chemoembolization (TACE). The digital twin...
The National Cancer Institute (NCI) awarded a $164,639 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Brown University to develop a novel pipeline for kidney segmentation and registration based on deep learning techniques. The goal is to improve treatment efficacy and reduce recurrence rates for image-guided thermal ablation (IGTA), a minimally invasive cancer treatment. Specifically, the research will focus on detecting and mitigating potentially undetected...
This Project Grant award, titled "EXPLOITING THERAPEUTIC VULNERABILITIES IN HEPATOCELLULAR CARCINOMA (ELEVATE)", is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research). The $2,678,459 award aims to advance the understanding of molecular mechanisms regulating non-alcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) and develop novel combinatorial treatment approaches. The award supports four research projects, an administrative core, a...
This Project Grant award of $157,000 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to unveil a novel mechanism of oncovirus-induced carcinogenesis. The primary awardee, Rutgers, The State University of New Jersey, will conduct long-read sequencing on hepatitis B virus (HBV)-positive tumors and cell lines to fully map HBV integrations and identify HBV integration-bridged chromosomal translocation events. This research aims to validate...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $275,092 to the University of Wisconsin-Madison to develop an accurate and robust targeting technique to enable transcostal histotripsy treatment of liver tumors. The goal is to improve histotripsy treatments of liver tumors by developing a clinically translatable workflow for targeting liver tumors through the ribs. The project includes quantifying the effect of intervening ribs on targeting accuracy, developing a machine learning model to predict targeting offsets, and incorporating the model to deliver patient-specific treatment plans in a rabbit liver tumor model. This work aims to expand the cohort of patients eligible for histotripsy therapy, which is a noninvasive, nonthermal, and nonionizing focal tumor treatment that has shown promise in a recent Phase I clinical trial for liver tumors. The award period runs from December 1, 2024 to June 30, 2027.